Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 14,602	$ 5,316
General and administrative	8,472	2,854
Change in fair value of contingent consideration	401	299
Total operating expenses	23,475	8,469
Operating loss	(23,475)	(8,469)
Other income, net
Interest income, net	2,077	113
Total other income, net	2,077	113
Net loss	(21,398)	(8,356)
Other comprehensive income (loss)
Net unrealized loss on marketable securities	(105)	0
Foreign currency translation adjustment	(1)	16
Total comprehensive loss	$ (21,504)	$ (8,340)
Net loss per common share basic	$ (0.59)	$ (0.88)
Net loss per common share diluted	$ (0.59)	$ (0.88)
Weighted-average common shares outstanding used to calculate basic net loss per common share	36,208,371	9,447,350
Weighted-average common shares outstanding used to calculate diluted net loss per common share	36,208,371	9,447,350